Gnc-035
Hematopoietic And Lymphoid System Neoplasm
Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05104775CT.gov A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gnc-035 (this asset) | Sichuan Baili Pharmaceutical Co., Ltd. | P1 | C · 39 |
| Adriamycin | OHSU Knight Cancer Institute | P4 | BBB |
| Dexasone | City of Hope Medical Center | P3 | BB |
| Teclistamab | Janssen Pharmaceutical K.K. | P2 | BB |
| Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf) | Gamida Cell ltd | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Bortezomib | OHSU Knight Cancer Institute | P4 | BB |
| Etoposide | Ciusss de L'Est de l'Île de Montréal | P2 | BB |
| Pembrolizumab | Vividion Therapeutics, Inc. | P3 | BB |
+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort
Other indications for Gnc-035
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P1/2 | CCC · 48 |
| Non-Hodgkin Lymphoma | — | P1/2 | CC · 43 |
| Breast Cancer | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AdriamycinOHSU Knight Cancer InstituteBBB
- DexasoneCity of Hope Medical CenterBB
- TeclistamabJanssen Pharmaceutical K.K.BB
- Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdBB
- CyclophosphamideNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Gnc-035 in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gnc-035-hematopoietic-and-lymphoid-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →